Zobrazeno 1 - 10
of 123
pro vyhledávání: ''
Autor:
Satoshi, Fukata, Keisuke, Mizutani, Shinkuro, Yamamoto, Takahira, Kuno, Hideo, Fukuhara, Shingo, Ashida, Takashi, Karashima, Keiji, Inoue
Publikováno v:
Anti-Cancer Drugs. 33:459-466
The objective was to evaluate the usefulness of sarcopenia and the neutrophil/lymphocyte ratio (NLR) as therapeutic efficacy predictors in patients who received pembrolizumab after platinum-based chemotherapy for advanced urothelial carcinoma (aUC).
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 33:e584-e589
This retrospective study was conducted to explore the effects of anlotinib as first-line treatment for patients with advanced lung adenocarcinoma. We retrospectively reviewed medical records of 60 patients with advanced lung adenocarcinoma, admitted
Autor:
Polat Olgun, Omer Diker
Publikováno v:
Anti-cancer drugs. 33(8)
Patients with advanced nonsmall cell lung cancer (NSCLC) who progress with immune checkpoint inhibitors (ICIs), salvage chemotherapy remains the only viable option for tumors that do not harbor genomic alterations. Data on the efficacy of salvage che
Autor:
Cuizhen Liu, Xinping Ye, Yanfeng Jiang, Guangzhi Zhu, Jing Tang, Tao Peng, Jie Ma, Zhiming Zeng, Jie Zeng, Fuchao Ma, Jinfeng Qiu, Lihua Yang
Publikováno v:
Anti-Cancer Drugs. 32:1093-1098
This study was to explore the efficacy and safety of camrelizumab combined with apatinib in patients with advanced liver cancer. Moreover, the relationship between peripheral blood parameters and tumor response rate was also investigated. Patients wi
Autor:
Tianwen Gao, Yanhong Zhao, Lei Wang, Tao Zhao, Weinan Guo, Guannan Zhu, Weigang Zhang, Qiong Shi, Lin Liu, Chunying Li, Yu Liu, Jianhong Zhao
Publikováno v:
Anti-Cancer Drugs. 32:1105-1110
Objectives Recombinant human interferon-α1b (IFN-α1b) is the first genetic engineered drug of China and is approved for cancer treatment by Chinese Food and Drug Administration. Although recombinant IFN-α1b is biologically and therapeutically acti
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many
Publikováno v:
Anti-Cancer Drugs
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel
Publikováno v:
Anti-Cancer Drugs. 32:210-214
Treatment options for unresectable local recurrence or metastatic well-differentiated/dedifferentiated liposarcoma (WDLS/DDLS) remain limited. Different liposarcoma subtypes have varying clinical features and sensitivities to treatment regimens. The